ArticleBioengineering & translational medicine2026
Evaluation of a functionalized chitosan and alginate multilayer conformal nanocoating toward improving islet survival in syngeneic mouse islet transplantation.
Article in Bioengineering & translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Human donor islets coated with functionalized chitosan and alginate nanoscale layers can restore normoglycemia in diabetic mice.Materials today. Bio · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Encapsulation of pancreatic islet transplants with nano-thin conformal coatings has been reported to maintain islet cell function and minimize immune rejection in type 1 diabetes (T1D) treatment. Our work investigated a novel combination of non-immunogenic polyelectrolytes, tetrahydropyran triazole phenyl-alginate (TZ-AL) and quaternized phosphocholine-chitosan (PC-QCH), for layer-by-layer self-assembly onto the surface of mouse islets. Building on previous work validating coating characteristics and biocompatibility using cell-derived spheroids, we assessed the immunoprotective properties of the polyelectrolyte coating. This was done through in vitro co-culture of the polyelectrolytes with mouse-derived splenocytes enriched for antigen-presenting cells (APCs) and syngeneic transplantation of coated mouse islets into STZ-induced diabetic mice. Results indicated that the polyelectrolytes may downregulate APC activation and maturation in vitro. In addition, coated islets successfully restored normoglycemia in syngeneic transplants, as demonstrated by blood glucose measurements, intraperitoneal glucose tolerance tests, and graft immunostaining. These results suggest that the polyelectrolyte coating may modulate APC activation and that coated islets exhibit therapeutic efficacy for glycemic control in T1D.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.